These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 34789668)

  • 41. Association between stool consistency and clinical variables among infants with cystic fibrosis: Findings from the BONUS study.
    Freeman AJ; Huang R; Heltshe SL; Gelfond D; Leung DH; Ramsey BR; Borowitz D; Sathe M;
    J Cyst Fibros; 2022 Sep; 21(5):830-836. PubMed ID: 35585010
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Moderate to severe and prolonged left lower-abdominal pain is the best symptom characterizing symptomatic uncomplicated diverticular disease of the colon: a comparison with fecal calprotectin in clinical setting.
    Tursi A; Elisei W; Picchio M; Giorgetti GM; Brandimarte G
    J Clin Gastroenterol; 2015 Mar; 49(3):218-21. PubMed ID: 24583746
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pancreatitis among patients with cystic fibrosis: correlation with pancreatic status and genotype.
    De Boeck K; Weren M; Proesmans M; Kerem E
    Pediatrics; 2005 Apr; 115(4):e463-9. PubMed ID: 15772171
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Digitoxin for Airway Inflammation in Cystic Fibrosis: Preliminary Assessment of Safety, Pharmacokinetics, and Dose Finding.
    Zeitlin PL; Diener-West M; Callahan KA; Lee S; Talbot CC; Pollard B; Boyle MP; Lechtzin N
    Ann Am Thorac Soc; 2017 Feb; 14(2):220-229. PubMed ID: 28006108
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A high prevalence of chronic gastrointestinal symptoms in adults with cystic fibrosis is detected using tools already validated in other GI disorders.
    Hayee B; Watson KL; Campbell S; Simpson A; Farrell E; Hutchings P; Macedo P; Perrin F; Whelan K; Elston C
    United European Gastroenterol J; 2019 Aug; 7(7):881-888. PubMed ID: 31428412
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fecal elastase-1 is superior to fecal chymotrypsin in the assessment of pancreatic involvement in cystic fibrosis.
    Walkowiak J; Herzig KH; Strzykala K; Przyslawski J; Krawczynski M
    Pediatrics; 2002 Jul; 110(1 Pt 1):e7. PubMed ID: 12093988
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fecal Calprotectin as a Useful Non-Invasive Screening Marker for Eosinophilic Gastrointestinal Disorder in Korean Children.
    Yoo IH; Cho JM; Joo JY; Yang HR
    J Korean Med Sci; 2020 May; 35(17):e120. PubMed ID: 32356420
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dynamics of soluble and cellular inflammatory markers in nasal lavage obtained from cystic fibrosis patients during intravenous antibiotic treatment.
    Hentschel J; Jäger M; Beiersdorf N; Fischer N; Doht F; Michl RK; Lehmann T; Markert UR; Böer K; Keller PM; Pletz MW; Mainz JG
    BMC Pulm Med; 2014 May; 14():82. PubMed ID: 24885494
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Distal intestinal obstruction syndrome: an important differential diagnosis for abdominal pain in patients with cystic fibrosis.
    Hort A; Hameed A; Middleton PG; Pleass HC
    ANZ J Surg; 2020 May; 90(5):681-686. PubMed ID: 31364217
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Disrupted intestinal microbiota and intestinal inflammation in children with cystic fibrosis and its restoration with Lactobacillus GG: a randomised clinical trial.
    Bruzzese E; Callegari ML; Raia V; Viscovo S; Scotto R; Ferrari S; Morelli L; Buccigrossi V; Lo Vecchio A; Ruberto E; Guarino A
    PLoS One; 2014; 9(2):e87796. PubMed ID: 24586292
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Diagnostic accuracy of fecal elastase 1 assay in patients with pancreatic maldigestion or intestinal malabsorption: a collaborative study of the Italian Society of Pediatric Gastroenterology and Hepatology.
    Carroccio A; Verghi F; Santini B; Lucidi V; Iacono G; Cavataio F; Soresi M; Ansaldi N; Castro M; Montalto G
    Dig Dis Sci; 2001 Jun; 46(6):1335-42. PubMed ID: 11414313
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sino nasal inhalation of isotonic versus hypertonic saline (6.0%) in CF patients with chronic rhinosinusitis - Results of a multicenter, prospective, randomized, double-blind, controlled trial.
    Mainz JG; Schumacher U; Schädlich K; Hentschel J; Koitschev C; Koitschev A; Riethmüller J; Prenzel F; Sommerburg O; Wiedemann B; Staab D; Gleiber W; Fischer R; Beck JF; Arnold C;
    J Cyst Fibros; 2016 Nov; 15(6):e57-e66. PubMed ID: 27267518
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Diagnostic value of faecal calprotectin in paediatric gastroenterology clinical practice.
    Berni Canani R; Rapacciuolo L; Romano MT; Tanturri de Horatio L; Terrin G; Manguso F; Cirillo P; Paparo F; Troncone R
    Dig Liver Dis; 2004 Jul; 36(7):467-70. PubMed ID: 15285526
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Specific Inhibition of the NLRP3 Inflammasome as an Antiinflammatory Strategy in Cystic Fibrosis.
    McElvaney OJ; Zaslona Z; Becker-Flegler K; Palsson-McDermott EM; Boland F; Gunaratnam C; Gulbins E; O'Neill LA; Reeves EP; McElvaney NG
    Am J Respir Crit Care Med; 2019 Dec; 200(11):1381-1391. PubMed ID: 31454256
    [No Abstract]   [Full Text] [Related]  

  • 55. Quality of life in clinically stable adult cystic fibrosis out-patients: associations with daytime sleepiness and sleep quality.
    Bouka A; Tiede H; Liebich L; Dumitrascu R; Hecker C; Reichenberger F; Mayer K; Seeger W; Schulz R
    Respir Med; 2012 Sep; 106(9):1244-9. PubMed ID: 22770684
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
    Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
    Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation.
    Horsley AR; Davies JC; Gray RD; Macleod KA; Donovan J; Aziz ZA; Bell NJ; Rainer M; Mt-Isa S; Voase N; Dewar MH; Saunders C; Gibson JS; Parra-Leiton J; Larsen MD; Jeswiet S; Soussi S; Bakar Y; Meister MG; Tyler P; Doherty A; Hansell DM; Ashby D; Hyde SC; Gill DR; Greening AP; Porteous DJ; Innes JA; Boyd AC; Griesenbach U; Cunningham S; Alton EW
    Thorax; 2013 Jun; 68(6):532-9. PubMed ID: 23396354
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study.
    Manz M; Burri E; Rothen C; Tchanguizi N; Niederberger C; Rossi L; Beglinger C; Lehmann FS
    BMC Gastroenterol; 2012 Jan; 12():5. PubMed ID: 22233279
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fecal calprotectin in systemic sclerosis and review of the literature.
    Marie I; Leroi AM; Menard JF; Levesque H; Quillard M; Ducrotte P
    Autoimmun Rev; 2015 Jun; 14(6):547-54. PubMed ID: 25661980
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology.
    Dolwani S; Metzner M; Wassell JJ; Yong A; Hawthorne AB
    Aliment Pharmacol Ther; 2004 Sep; 20(6):615-21. PubMed ID: 15352909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.